An investigator-initiated basket trial to evaluate VB10.16 in combination with a PD-L1 inhibitor in patients diagnosed with HPV16-positive anal, penile, vaginal and/or vulvar cancer who are no longer eligible for curative treatment
Latest Information Update: 22 Dec 2022
At a glance
- Drugs VB10 16 (Primary) ; Programmed cell death-1 ligand-1 inhibitors
- Indications Anal cancer; Penile cancer; Vulvovaginal cancer
- Focus Therapeutic Use
Most Recent Events
- 22 Dec 2022 New trial record